| A proportional hazards model for the subdistribution of a competing risk JP Fine, RJ Gray Journal of the American statistical association 94 (446), 496-509, 1999 | 14328 | 1999 |
| Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer A Sandler, R Gray, MC Perry, J Brahmer, JH Schiller, A Dowlati, ... New England Journal of Medicine 355 (24), 2542-2550, 2006 | 7541 | 2006 |
| A class of K-sample tests for comparing the cumulative incidence of a competing risk RJ Gray The Annals of statistics, 1141-1154, 1988 | 5396 | 1988 |
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 379 (9814), 432-444, 2012 | 2324 | 2012 |
| Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 379 (2), 111-121, 2018 | 2271 | 2018 |
| Prospective validation of a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 373 (21), 2005-2014, 2015 | 1574 | 2015 |
| Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 S Adams, RJ Gray, S Demaria, L Goldstein, EA Perez, LN Shulman, ... Journal of clinical oncology 32 (27), 2959-2966, 2014 | 1432 | 2014 |
| Annual hazard rates of recurrence for breast cancer after primary therapy. T Saphner, DC Tormey, R Gray Journal of clinical oncology 14 (10), 2738-2746, 1996 | 1040 | 1996 |
| Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system CA Hudis, WE Barlow, JP Costantino, RJ Gray, KI Pritchard, ... Journal of Clinical Oncology 25 (15), 2127-2132, 2007 | 864 | 2007 |
| Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers S Loi, D Drubay, S Adams, G Pruneri, PA Francis, M Lacroix-Triki, ... Journal of clinical oncology 37 (7), 559-569, 2019 | 767 | 2019 |
| Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 386 (10001), 1353-1361, 2015 | 691 | 2015 |
| Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis RJ Gray Journal of the American Statistical Association 87 (420), 942-951, 1992 | 686 | 1992 |
| A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast LJ Solin, R Gray, FL Baehner, SM Butler, LL Hughes, C Yoshizawa, ... Journal of the National Cancer Institute 105 (10), 701-710, 2013 | 598 | 2013 |
| Computing an exact confidence interval for the common odds ratio in several 2× 2 contingency tables CR Mehta, NR Patel, R Gray Journal of the American Statistical Association 80 (392), 969-973, 1985 | 572 | 1985 |
| Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group A Recht, R Gray, NE Davidson, BL Fowble, LJ Solin, FJ Cummings, ... Journal of Clinical Oncology 17 (6), 1689-1689, 1999 | 562 | 1999 |
| Calculation of polychotomous logistic regression parameters using individualized regressions CB Becg, R Gray Biometrika 71 (1), 11-18, 1984 | 556 | 1984 |
| Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. T Saphner, DC Tormey, R Gray Journal of Clinical Oncology 9 (2), 286-294, 1991 | 541 | 1991 |
| Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC# 704865) in patients with advanced non-squamous non-small cell lung cancer … AB Sandler, R Gray, J Brahmer, A Dowlati, JH Schiller, MC Perry, ... Journal of Clinical Oncology 23 (16_suppl), LBA4-LBA4, 2005 | 524 | 2005 |
| Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer JA Sparano, RJ Gray, PM Ravdin, DF Makower, KI Pritchard, KS Albain, ... New England journal of medicine 380 (25), 2395-2405, 2019 | 501 | 2019 |
| Outcomes for elderly, advanced-stage non–small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern … SS Ramalingam, SE Dahlberg, CJ Langer, R Gray, CP Belani, ... Journal of Clinical Oncology 26 (1), 60-65, 2008 | 464 | 2008 |
